What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2, Pre-Registered Trial).

What question did this study set out to answer?

Evaluate the efficacy of the Cladillac conditioning regimen in high-risk AML patients.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 trial shows 58% progression-free survival in high-risk AML, suggesting novel Cladillac regimen may enhance outcomes.

Evaluate the efficacy of the Cladillac conditioning regimen in high-risk AML patients.
Phase 2 trial with 50 patients aged 18-70 years.
Conditioning involved busulfan, cladribine, thiotepa, and venetoclax.
Post-transplant cyclophosphamide was used for GVHD prophylaxis.
Primary endpoint was progression-free survival (PFS).
One-year PFS was 60% and three-year PFS was 58%.
Three-year overall survival was 64%, with 26% disease relapse rate.
TP53 wild-type patients had superior outcomes with an OS of 74%.
20% experienced grade 2–4 acute GVHD.

Bashir et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 trial shows 58% progression-free survival in high-risk AML, suggesting novel Cladillac regimen may enhance outcomes.

Evaluate the efficacy of the Cladillac conditioning regimen in high-risk AML patients.
Phase 2 trial with 50 patients aged 18-70 years.
Conditioning involved busulfan, cladribine, thiotepa, and venetoclax.
Post-transplant cyclophosphamide was used for GVHD prophylaxis.
Primary endpoint was progression-free survival (PFS).
One-year PFS was 60% and three-year PFS was 58%.
Three-year overall survival was 64%, with 26% disease relapse rate.
TP53 wild-type patients had superior outcomes with an OS of 74%.
20% experienced grade 2–4 acute GVHD.

Bashir et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark